Data shows Cladribine benefits persist in RRMS patients

Mavenclad is an oral treatment for relapsing MS and active secondary progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Data shows Cladribine benefits persist in RRMS patients

Post by MSUK » Tue Apr 19, 2016 4:33 am

The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a study presented at the 68th American Academy of Neurology Annual Meeting...Read More - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post